<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02145065</url>
  </required_header>
  <id_info>
    <org_study_id>PAX-0314</org_study_id>
    <nct_id>NCT02145065</nct_id>
  </id_info>
  <brief_title>First-in-man Evaluation of a Novel, Microcrystalline Paclitaxel Coated Balloon for Treatment of Femoropopliteal Artery Disease (PAX-r)</brief_title>
  <acronym>PAX</acronym>
  <official_title>Prospective, Pivotal, First - in Man Clinical Trial of the Safety and Efficacy of a Novel Microcrystalline Paclitaxel Coated Balloon for Treatment of Femoropopliteal Artery Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Balton Sp.zo.o.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>American Heart of Poland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Balton Sp.zo.o.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this pivotal, first in man study will be to evaluate safety and efficacy of
      the novel, microcrystalline paclitaxel coated balloon (mcPCB, PAK, Balton) in the treatment
      of femoropopliteal artery disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Although clinically effective, the manufacturing process of first generation PCB coatings
      contributed to inconsistent drug concentrations, particulate formations on the balloon
      surface and their shedding during the interventional procedures. As a consequence
      developments of new PCB coatings have been proposed to address consistency, uniformity, small
      particle drug coverage, which may potentially contribute to improved vessel healing profile
      and improved clinical outcomes. Nevertheless, data on the safety and efficacy of this novel
      coating developments in the clinical setting remain limited. Previously in the experimental
      model, the investigators reported that delivery of paclitaxel via a novel mcPCB resulted in
      low long-term tissue retention of paclitaxel, however displayed reduced neointimal
      proliferation and favorable healing profile. Therefore in current clinical trial the
      investigators will address the feasibility and safety of the mcPCB (PAK, Balton) in the
      treatment of femoropopliteal restenotic disease in a prospective, randomized manner when
      compared to plain balloon angioplasty (PBA). The efficacy analysis will be observational and
      evaluated post-hoc, with no prespecified criteria.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>September 2014</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">July 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Angiographic late lumen loss</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety - Device related adverse events</measure>
    <time_frame>30 days, 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Critical limb ischemia</measure>
    <time_frame>30 days, 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Device Success</measure>
    <time_frame>at procedure</time_frame>
    <description>Successful delivery and deployment of the first inserted study device (in overlapping setting a successful delivery and deployment of the first and second study device) at the intended target lesion and successful withdrawal of the study device with attainment of final residual stenosis of less than 30% of the target lesion by quantitative vessel angiography (QVA).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Lesion Revascularization</measure>
    <time_frame>6, 12, 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target vessel revascularization</measure>
    <time_frame>6, 12, 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Primary patency of treated segment</measure>
    <time_frame>6, 12, 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treated limb amputation</measure>
    <time_frame>30 days, 6 months</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in ankle-brachial index</measure>
    <time_frame>pre-procedure, 3,6 and 12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in Walking Impairment Questionnaire (WIQ)</measure>
    <time_frame>pre procedure, 3, 6 and 12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Flow velocity in doppler ultrasonography</measure>
    <time_frame>3, 6 and 12 months</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">66</enrollment>
  <condition>Peripheral Artery Disease</condition>
  <condition>Femoropopliteal Artery Disease</condition>
  <arm_group>
    <arm_group_label>Plain Balloon Angioplasty</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Plain Balloon Angioplasty</description>
  </arm_group>
  <arm_group>
    <arm_group_label>microcrystalline Paclitaxel Coated Balloon (PAK)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>plain balloon angioplasty followed by mcPCB dilation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Local drug delivery via microcrystalline paclitaxel balloon coating (PAK,Balton, Poland)</intervention_name>
    <arm_group_label>microcrystalline Paclitaxel Coated Balloon (PAK)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Plain balloon angioplasty, uncoated balloon (Neptun, Balton, Poland)</intervention_name>
    <arm_group_label>Plain Balloon Angioplasty</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 18 y.o.

          -  Claudication in Rutherford Class 1-5,

          -  Lesion in the femoropopliteal artery defined as &gt;50% and &lt; 99% diameter stenosis with
             length of up to 10 cm in vessel diameter of 3-7 mm

          -  Chronic total occlusions of length less than 100 mm

          -  Ability to cross the lesions with a guidewire.

        Exclusion Criteria:

          -  Critical acute or chronic limb ischemia

          -  Acute coronary syndrome

          -  Chronic kidney disease stage III-V

          -  Restenotic lesion

          -  Femoropopliteal graft

          -  Known allergy to clopidogrel or aspirin

          -  History of stroke within past 6 months

          -  Age &gt; 80 y.o.

          -  Life expectancy &lt; 2 years
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Przemysław Nowakowski, M.D., PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>American Heart of Poland, Katowice, Poland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Piotr P Buszman, M.D., PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>American Heart of Poland, Katowice, Poland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Lesser-Poland Cardiovascular Center of American Heart of Poland</name>
      <address>
        <city>Chrzanów</city>
        <zip>32-500</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <reference>
    <citation>Buszman PP, Milewski K, Zurakowski A, Pajak J, Jelonek M, Gasior P, Peppas A, Tellez A, Granada JF, Buszman PE. Experimental evaluation of pharmacokinetic profile and biological effect of a novel paclitaxel microcrystalline balloon coating in the iliofemoral territory of swine. Catheter Cardiovasc Interv. 2014 Feb;83(2):325-33. doi: 10.1002/ccd.24982. Epub 2013 Oct 23.</citation>
    <PMID>23703720</PMID>
  </reference>
  <reference>
    <citation>Tepe G, Zeller T, Albrecht T, Heller S, Schwarzwälder U, Beregi JP, Claussen CD, Oldenburg A, Scheller B, Speck U. Local delivery of paclitaxel to inhibit restenosis during angioplasty of the leg. N Engl J Med. 2008 Feb 14;358(7):689-99. doi: 10.1056/NEJMoa0706356.</citation>
    <PMID>18272892</PMID>
  </reference>
  <reference>
    <citation>Werk M, Langner S, Reinkensmeier B, Boettcher HF, Tepe G, Dietz U, Hosten N, Hamm B, Speck U, Ricke J. Inhibition of restenosis in femoropopliteal arteries: paclitaxel-coated versus uncoated balloon: femoral paclitaxel randomized pilot trial. Circulation. 2008 Sep 23;118(13):1358-65. doi: 10.1161/CIRCULATIONAHA.107.735985. Epub 2008 Sep 8. Erratum in: Circulation. 2008 Oct 14;118(16):e670.</citation>
    <PMID>18779447</PMID>
  </reference>
  <reference>
    <citation>Scheller B, Hehrlein C, Bocksch W, Rutsch W, Haghi D, Dietz U, Böhm M, Speck U. Treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter. N Engl J Med. 2006 Nov 16;355(20):2113-24. Epub 2006 Nov 13.</citation>
    <PMID>17101615</PMID>
  </reference>
  <reference>
    <citation>Scheinert D, Duda S, Zeller T, Krankenberg H, Ricke J, Bosiers M, Tepe G, Naisbitt S, Rosenfield K. The LEVANT I (Lutonix paclitaxel-coated balloon for the prevention of femoropopliteal restenosis) trial for femoropopliteal revascularization: first-in-human randomized trial of low-dose drug-coated balloon versus uncoated balloon angioplasty. JACC Cardiovasc Interv. 2014 Jan;7(1):10-9. doi: 10.1016/j.jcin.2013.05.022.</citation>
    <PMID>24456716</PMID>
  </reference>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 20, 2014</study_first_submitted>
  <study_first_submitted_qc>May 21, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 22, 2014</study_first_posted>
  <last_update_submitted>June 14, 2017</last_update_submitted>
  <last_update_submitted_qc>June 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 15, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>paclitaxel coated balloon</keyword>
  <keyword>restenosis</keyword>
  <keyword>Femoropopliteal artery disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Arterial Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

